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Reply to J.-E. Bibault et al, B. Tombal,
and C. Cattrini et al
We would like to thank Bibault et al,1 Tombal,2 and Cattrini
et al3 for their insightful comments on the STOMP (Surveillance
or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer
Recurrence) trial.4 We would like to take this opportunity to address
some of the important issues raised.
The three letters argue that androgen-deprivation therapy
(ADT) is the standard of care for patients included in the STOMP
trial. Our patients had a biochemical recurrence after maximal
local therapy, with up to three nodal or metastatic lesions on
choline positron emission tomography–computed tomography
(PET-CT); a majority had negative conventional imaging. Both
Tombal2 and Cattrini et al3 argue that the TOAD (Timing of
Androgen Deprivation) trial reported in 2016 clearly indicates that
ADT is the standard of care and that our control arm with sur-
veillance is unjustified.5 Firstly, we want to indicate that our trial
was designed in 2011 and recruited the last patient in August 2015,
well before the TOAD trial was reported. Important to highlight is
the fact that a majority of patients in the TOAD trial experienced
relapse after primary radiotherapy, in contrast to patients in the
STOMP trial (. 60% v 24%).4,5 Several studies have already in-
dicated that the pattern of recurrence is different, and we expect
that a majority of patients in the TOAD trial experienced a local
relapse.6,7 Local recurrences were excluded in the STOMP trial.
Additionally, the TOAD trial was not able to demonstrate an overall
survival benefit in the prostate-specific antigen relapse group, with
an unadjusted hazard ratio for overall survival of 0.58 (95% CI,
0.30 to 1.12), nor was there a prostate cancer–specific survival
benefit.5 As Brand and Parker stated, “taken together with the lack
of statistical significance, it is clear that any difference in overall
survival is consistent with the null hypothesis and the play of
chance.”8(p522) Secondly, the 2017 European Urology Association
guidelines still include the following statement on ADT in this
setting: “Based on the lack of definitive efficacy and the un-
doubtedly associated significant side effects, not all patients with
recurrence after primary curative therapy should receive standard
HT.”9(p72) The recommendation in 2011 and in 2017 was and still
is: “Do not routinely offer ADT to asymptomatic men with bio-
chemical recurrence”9(p76) (grade A recommendation, level 3
evidence). Consequently, we and others8-10 are not convinced
that ADT is the only standard of care for patients such as those
included in the STOMP trial. In the three letters, the relevance of
our primary end point of ADT-free survival is questioned. We
agree with the authors that this is not a hard end point, but we
disagree that it is unethical or subjective or biased. The start of
ADTwas prespecified at trial design (local progression, progression
to. three metastases, or symptomatic progression), and as such, it
was not subjective or biased. We believe that at conception of the
trial and in agreement with current European Urology Association
guidelines, surveillance is still a valid and ethical option in this
specific patient group.8-10
Cattrini et al3 argue that ADT plus docetaxel or abiraterone is
standard of care for oligorecurrent prostate cancer, based on the
results of STAMPEDE (Systemic Therapy in Advancing or Met-
astatic Prostate Cancer: Evaluation of Drug Efficacy).11 Patients in
both STAMPEDE and CHAARTED (Chemohormonal Therapy
Versus Androgen Ablation Randomized Trial for Extensive Disease
in Prostate Cancer) are not comparable to those in STOMP.11 A
recent update of the CHAARTED trial indicated that patients with
low-volume disease do not benefit from ADT plus docetaxel.12
Consequently, we believe that the suggestion by Cattrini et al is
not supported by the trial data or the guidelines.
Tombal2 argues that the sensitivity and specificity of choline
and even prostate-specific membrane antigen PET-CT are in-
sufficient to guide metastasis-directed treatment (MDT). First of
all, we agree that PET-CT misses microscopic disease and that
repeated MDT courses might be warranted; nevertheless, with this
approach, no grade $ 2 toxicity was reported, nor was there
a decline in quality of life, in contrast to studies providing im-
mediate ADT.5 Therefore, we were surprised that both Tombal and
Cattrini et al3 believe PET-CT imaging is good enough to de-
termine whether to start immediate systemic therapy. Secondly, the
question of which sensitivity/specificity cutoff should be used for
any novel imaging before it is used in a clinical trial remains. For
example, repeated magnetic resonance imaging–based stereotactic
radiosurgery is becoming standard of care for brain metastases in
favor of whole-brain radiotherapy plus stereotactic radiosurgery,
despite 50% of patients experiencing relapse within the brain
within 1 year.13 Although the sensitivity of magnetic resonance
imaging in the setting of brain metastases is far from perfect, the
strategy of repeated MDT is appealing because of less toxicity and
comparable survival.13 Consequently, we believe that modern PET
tracers are at least ready for inclusion in prostate cancer clinical
trials.
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